At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 957 enrolled
Drug / intervention
PoliorixTM +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety of a Booster Dose of GlaxoSmithKline Biologicals' IPV (PoliorixTM) in Healthy Chinese Toddlers
In Brief
A Phase 3 clinical trial evaluating PoliorixTM and Infanrix+Hib for Poliomyelitis. Completed, enrolled 957 participants across 2 sites.
Detailed Summary
This study aims to evaluate the persistence of anti-poliovirus antibodies in toddlers aged 18 months who were primed with oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in the primary study. The study will also assess the immunogenicity and reactogenicity of a booster dose of IPV in subjects primed with three doses of IPV.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPoliomyelitis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartApr 2011
Primary CompletionSep 2011
TodayJul 2026
First PostedMar 25, 2011
Enrollment StartApr 25, 2011
Primary CompletionSep 19, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.3 years ago
Interventions
PoliorixTMbiological
Single dose, intramuscular administration
Infanrix+Hibbiological
Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.